---
title: "Compass gains on new late-stage trial data for psychedelic therapy in depression"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291924843.md"
description: "Compass Pathways (CMPS) shares rose ~8% in premarket trading after announcing positive late-stage trial data for its psychedelic therapy COMP360. The 26-week results from the Phase 3 COMP006 trial confirmed rapid onset and durable efficacy for treatment-resistant depression, with no new safety issues. A second dose showed improved clinical benefit over a single dose. The company expects to conclude its rolling New Drug Application submission in Q4 and aims for an H1 2027 launch, pending FDA approval."
datetime: "2026-07-07T11:30:40.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291924843.md)
  - [en](https://longbridge.com/en/news/291924843.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291924843.md)
---

# Compass gains on new late-stage trial data for psychedelic therapy in depression


### Related Stocks

- [CMPS.US](https://longbridge.com/en/quote/CMPS.US.md)

## Related News & Research

- [Compass Pathways publishes investor presentation on COMP360 psilocybin program, FDA filing progress and launch plans](https://longbridge.com/en/news/294963906.md)
- [CMPS: COMP360's positive Phase III results and strong commercial readiness position it for a 2027 launch](https://longbridge.com/en/news/294973356.md)
- [CMPS: Q2 2026 net loss widened to $253.8M; Phase 3 TRD milestones achieved; cash runway into 2028](https://longbridge.com/en/news/294951377.md)
- [RARE: Record Q2 revenue and upcoming gene therapy launches position the company for 2027 profitability](https://longbridge.com/en/news/294883644.md)
- [Lexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (Rmat) Designation For Lx2020](https://longbridge.com/en/news/294966104.md)